Increased risk for cancer of the breast due to previous medication.
Fifteen patients presenting one or more risk factors for cancer of the breast, who also received medication with prolactin-stimulating effects, were selected. The medication was by hormone derivatives or by non-hormone drugs used for processes other than oncologic . In all cases the medication was for long periods, three or more years, with the exception of one case, where the correlation with the unfavourable evolution of the cancer process was more evident. In patients presenting the classic risk factors for cancer of the breast, it is recommended to avoid the prescription of drugs having a prolactin-stimulating effect. The association of both circumstances (risk factors and prolactin-stimulating medication) is considered as an increased risk for cancer of the breast.
D004092:20-alpha-Dihydroprogesterone / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000009:adverse effects; D000662:Amphetamines / Q000009:adverse effects; D001943:Breast Neoplasms / Q000139:chemically induced*; D002927:Cimetidine / Q000009:adverse effects; D003270:Contraceptive Agents / Q000009:adverse effects*; D004958:Estradiol / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008750:Methyldopa / Q000009:adverse effects; D008875:Middle Aged; D010640:Phenothiazines / Q000009:adverse effects; D011388:Prolactin / Q000378:metabolism; D011619:Psychotropic Drugs / Q000009:adverse effects*; D011800:Quinestrol / Q000009:adverse effects; D012306:Risk; D013997:Time Factors
D000662:Amphetamines; D003270:Contraceptive Agents; D010640:Phenothiazines; D011619:Psychotropic Drugs; D004092:20-alpha-Dihydroprogesterone; D000639:Amitriptyline; D004958:Estradiol; D008750:Methyldopa; D002927:Cimetidine; D011388:Prolactin; D011800:Quinestrol; C002027:estradiol enanthate